combination glp-1 and sglt2 Inhibitors Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application Combining glucagon-like peptide-1 receptor agonists

Remember: Constipation is a common side effect of GLP-1 agonists, but it's manageable with the right strategies

CVS says it cant make enough money covering a million Americans just as it celebrates nearly $2 billion in quarterly profits and doubles down on high-dollar weight-loss drugs.

Overcoming access challenges with transitional assistance The market access environment for new launch products has become progressively restrictive with payers enforcing more prior authorizations, step edits, and blocks than ever before

This clinically grounded guide walks you through the 10 most important lab questions to raise with your doctor before and during treatment.

Employers can't shirk responsibility for novel weight loss drugs forever, executives argued at a recent Newsweek event.

These adaptations position irisin as a promising therapeutic target for preventing metabolic disorders and optimizing exercise protocols